Abstract:Introduction Recent developments characterizing the pathophysiological basis of infection in the Coronavirus disease - 19 (COVID-19) have stirred great interest in studying this disease outside the purview of respiratory involvement and especially focusing on the gastrointestinal (GI) system. The present study involving a large cohort of COVID-19-infected patients reports on the characteristics of GI manifestations in patients infected with COVID-19 as well as the predictive role in their association with disease severity and adverse outcomes. Methods A retrospective cohort study was carried out in a tertiary care hospital in northern India. Descriptive analysis of GI symptoms was carried out followed by predictive analysis assessing COVID-19 severity and with the primary endpoint of 28-day in-hospital all-cause mortality. Results Of 3842 hospitalized COVID-19 patients, 2113 (55%) were symptomatic. GI symptoms were present in 163 (7.1%) patients. Common GI symptoms were diarrhea 65 (3.1%), anorexia 61 (2.9%) and vomiting 37 (1.8%). Mild and moderate-to-severe disease was seen in 1725 (81.6%) and 388 (18.4%) patients, respectively. Logistic regression showed greater odds of moderate-to-severe disease in patients with any GI symptoms (odds ratio [OR] 1.849, 95% CI 1.289–2.651 [ p = 0.001]) and anorexia in particular (OR 2.797, 95% CI 1.647–4.753 [ p = 0.001]); however, on multivariable-analysis, this association lost its significance. A total of 172 patients succumbed to illness. In the Cox proportional hazards model for mortality, patients with any GI symptom (HR 2.184, 95 CI 1.439–3.317 [ p < 0.001]) and anorexia (HR 3.556, 95% CI 2.155–5.870 [ p < 0.001]) had higher risk. In multi-variable analysis after adjustment to age, sex, oxygen saturation and comorbidities, the presence of any GI symptom was a significant predictor of mortality (hazard ratio adjusted [HR adj ] 1.758, 95% CI 1.147–2.694 [ p = 0.010]). Conclusion GI symptoms were common among patients infected with COVID-19. The presence of any GI symptom was a significant predictor of the risk of mortality after adjustment to respiratory failure, age, sex and pre-existing comorbidities. The clinical and pathophysiological basis of these associations has been explored.

In situ observation of nanograin rotation and deformation in nacre.

COVID-19 and the Human Gut Microbiome: An Under-Recognized Association

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

Gastrointestinal manifestations in symptomatic Coronavirus disease - 19 patients and its relevance in predicting severity and outcome

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges

Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential

Association of Gut Microbiota with Inflammatory Bowel Disease and COVID-19 Severity: A Possible Outcome of the Altered Immune Response

COVID-19 and Gut Injury

[LIPOID DERMATO-ARTHRITIS, RETICULO-HISTIOCYTOSIS OF THE SKIN AND JOINTS].

Clinical Insights into the Gastrointestinal Manifestations of COVID-19

COVID-19 and Gut Microbiota: A Potential Connection

Impact of COVID-19 on the Gut: A Review of the Manifestations, Pathology, Management, and Challenges

COVID-19 and the digestive system: A comprehensive review

Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms

Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity

The effect of azathioprine, hydrocortisone and trimethazone on the occurrence of active lymphocytes in liver of endotoxin treated rabbits.

Gastrointestinal Microenvironment and the Gut-Lung Axis in the Immune Responses of Severe COVID-19

I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections

The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19

Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential